

Attorney Docket No.: 3985.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Application No.: 09/398,365

Group Art Unit: 1656

Filed: September 17, 1999

Examiner: J. Siew

Confirmation No: 9987

For: Acylated Insulin

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

10/08/2003 10:09 FAX 609 919 7741

10/08/2003 10:09 FAX 609 919 7741

Attorney Docket No. 3985.240-US

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The supplemental information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: October 8, 2003

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
OCT 10 2003

23650

PATENT TRADEMARK OFFICE

Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. 3985.240 US	Serial No. 09/398,365
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Havelund et al.	
(Use several sheets if necessary)		Filing date September 17, 1999	Group 1656

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MEMBERS of the public may apply for a copy of the information contained in this document by writing to the Secretary, Department of Environment, 100 Gloucester Street, Dublin 1, Ireland.